Your browser doesn't support javascript.
loading
A Stereocontrolled Synthesis of a Phosphorothioate Cyclic Dinucleotide-Based STING Agonist.
Kempson, James; Zhang, Huiping; Hou, Xiaoping; Cornelius, Lyndon; Zhao, Rulin; Wang, Bei; Hong, Zhenqiu; Oderinde, Martins S; Pawluczyk, Joseph; Wu, Dauh-Rurng; Sun, Dawn; Li, Peng; Yip, Shiuhang; Smith, Aaron; Caceres-Cortes, Janet; Aulakh, Darpandeep; Sarjeant, Amy A; Park, Peter K; Harikrishnan, Lalgudi S; Qin, Lan-Ying; Dodd, Dharmpal S; Fink, Brian; Vite, Gregory; Mathur, Arvind.
Afiliación
  • Kempson J; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Zhang H; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Hou X; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Cornelius L; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Zhao R; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Wang B; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Hong Z; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Oderinde MS; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Pawluczyk J; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Wu DR; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Sun D; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Li P; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Yip S; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Smith A; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Caceres-Cortes J; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Aulakh D; Materials Science & Engineering, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States.
  • Sarjeant AA; Materials Science & Engineering, Bristol-Myers Squibb Company, New Brunswick, New Jersey 08903, United States.
  • Park PK; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Harikrishnan LS; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Qin LY; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Dodd DS; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Fink B; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Vite G; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
  • Mathur A; Research and Early Development, Bristol-Myers Squibb Company, Princeton, New Jersey 08543-4000, United States.
J Org Chem ; 86(13): 8851-8861, 2021 07 02.
Article en En | MEDLINE | ID: mdl-34126006
ABSTRACT
We describe a stereodefined synthesis of the newly identified non-natural phosphorothioate cyclic dinucleotide (CDN) STING agonist, BMT-390025. The new route avoids the low-yielding racemic approach using P(III)-based reagents, and the stereospecific assembly of the phosphorothioate linkages are forged via the recently invented P(V)-based platform of the so-called PSI (Ψ) reagent system. This P(V) approach allows for the complete control of chirality of the P-based linkages and enabled conclusive evidence of the absolute configuration. The new approach offers robust procedures for preparing the stereodefined CDN in eight steps starting from advanced nucelosides, with late-stage direct drop isolations and telescoped steps enabling an efficient scale-up that proceeded in an overall 15% yield to produce multigram amounts of the CDN.

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Org Chem Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: J Org Chem Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos